Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update
| Autor: | Su H. Wang, Jessica P. Hwang, Andrew P. Loehrer, Devena E. Alston-Johnson, Norah A. Terrault, Sarah P. Hammond, Banu Symington, Melisa L. Wong, Jordan J. Feld, Donna R. Cryer, Andrew S. Artz, Mark R. Somerfield, Anita L. Sabichi, Dawn L. Hershman |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Hepatitis B virus
Cancer Research medicine.medical_specialty MEDLINE Antineoplastic Agents Antibodies Viral medicine.disease_cause Antiviral Agents 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Neoplasms Internal medicine Secondary Prevention medicine Electronic Health Records Humans 030212 general & internal medicine Patient Care Team Secondary prevention Hepatitis B Surface Antigens Patient care team biology business.industry virus diseases Neoplasms therapy Cancer Hepatitis B medicine.disease Hepatitis B Core Antigens digestive system diseases Oncology Immunoglobulin G 030220 oncology & carcinogenesis biology.protein Virus Activation Antibody business Stem Cell Transplantation |
| Zdroj: | Journal of Clinical Oncology. 38:3698-3715 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.20.01757 |
| Popis: | PURPOSE This Provisional Clinical Opinion update presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management. PROVISIONAL CLINICAL OPINION All patients anticipating systemic anticancer therapy should be tested for HBV by 3 tests—hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) total immunoglobulin (Ig) or IgG, and antibody to hepatitis B surface antigen—but anticancer therapy should not be delayed. Findings of chronic HBV (HBsAg-positive) or past HBV (HBsAg-negative and anti-HBc–positive) infection require HBV reactivation risk assessment. Patients with chronic HBV receiving any systemic anticancer therapy should receive antiviral prophylactic therapy through and for minimum 12 months following anticancer therapy. Hormonal therapy alone should not pose a substantial risk of HBV reactivation in patients with chronic HBV receiving hormonal therapy alone; these patients may follow noncancer HBV monitoring and treatment guidance. Coordination of care with a clinician experienced in HBV management is recommended for patients with chronic HBV to determine HBV monitoring and long-term antiviral therapy after completion of anticancer therapy. Patients with past HBV infection undergoing anticancer therapies associated with a high risk of HBV reactivation, such as anti-CD20 monoclonal antibodies or stem-cell transplantation, should receive antiviral prophylaxis during and for minimum 12 months after anticancer therapy completion, with individualized management thereafter. Careful monitoring may be an alternative if patients and providers can adhere to frequent, consistent follow-up so antiviral therapy may begin at the earliest sign of reactivation. Patients with past HBV undergoing other systemic anticancer therapies not clearly associated with a high risk of HBV reactivation should be monitored with HBsAg and alanine aminotransferase during cancer treatment; antiviral therapy should commence if HBV reactivation occurs. Additional information is available at www.asco.org/supportive-care-guidelines . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|